Difference between revisions of "Malignant peritoneal mesothelioma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - ":Section editor transclusions|" to ":Editorial board transclusions|") |
m (→NCCN) |
||
| Line 14: | Line 14: | ||
*'''2020:''' Kusamura et al. [https://doi.org/10.1016/j.ejso.2020.02.011 Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up] | *'''2020:''' Kusamura et al. [https://doi.org/10.1016/j.ejso.2020.02.011 Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up] | ||
==[https://www.nccn.org/ NCCN]== | ==[https://www.nccn.org/ NCCN]== | ||
| − | *[https://www.nccn.org/professionals/physician_gls/pdf/mpem.pdf NCCN Guidelines - | + | *[https://www.nccn.org/professionals/physician_gls/pdf/mpem.pdf NCCN Guidelines - Mesothelioma: Peritoneal] |
| + | |||
=Advanced or metastatic disease, subsequent lines of therapy= | =Advanced or metastatic disease, subsequent lines of therapy= | ||
==Atezolizumab & Bevacizumab {{#subobject:8ahgy7|Regimen=1}}== | ==Atezolizumab & Bevacizumab {{#subobject:8ahgy7|Regimen=1}}== | ||
Revision as of 18:45, 5 September 2023
| Section editor | |
|---|---|
 |
Marjorie G. Zauderer, MD, MS, FACP Memorial Sloan Kettering Cancer Center New York, NY, USA |
1 regimens on this page
1 variants on this page
|
Guidelines
EURACAN/PSOGI
- 2020: Kusamura et al. Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up
NCCN
Advanced or metastatic disease, subsequent lines of therapy
Atezolizumab & Bevacizumab
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Raghav et al. 2021 (MDACC 2016-0861) | 2017-2019 | Phase 2 |
Immunotherapy
- Atezolizumab (Tecentriq) 1200 mg IV once on day 1
Targeted therapy
- Bevacizumab (Avastin) 15 mg/kg IV once on day 1
21-day cycles
References
- MDACC 2016-0861: Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov. 2021 Nov;11(11):2738-2747. Epub 2021 Jul 14. link to original article link to PMC article contains dosing details in manuscript PubMed NCT03074513